Evidence map›Paper›PMID 31821904›Full record

SynthesisAmerican heart journal2020

Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction.

Dan Yang, Connor Galen O'Brien, Gentaro Ikeda, Jay H Traverse, Doris A Taylor, Timothy D Henry, Roberto Bolli, Phillip C Yang

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in American heart journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. New treatment methods for myocardial infarction.Frontiers in cardiovascular medicine · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Dan YangState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Division of Cardiovascular Medicine, Department of Medicine, and Cardiovascular Institute, Stanford University School of Medicine, CA, USA.
Connor Galen O'BrienDivision of Cardiovascular Medicine, Department of Medicine, and Cardiovascular Institute, Stanford University School of Medicine, CA, USA.
Gentaro IkedaDivision of Cardiovascular Medicine, Department of Medicine, and Cardiovascular Institute, Stanford University School of Medicine, CA, USA.
Jay H TraverseMinneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.
Doris A TaylorRegenerative Medicine Research, Texas Heart Institute, PO Box 20345, Houston, TX, USA.
Timothy D HenryThe Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, OH, USA.
Roberto BolliInstitute of Molecular Cardiology, University of Louisville, KY, USA.
Phillip C YangDivision of Cardiovascular Medicine, Department of Medicine, and Cardiovascular Institute, Stanford University School of Medicine, CA, USA. Electronic address: phillip@stanford.edu.
Cardiovascular Institute of the South · USAbbott Northwestern Hospital · USHealth Net · USStanford University · USUniversity of Louisville · US

Funding

Tumor Necrosis Factor Modulation of CPCsP01HL078825 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2005 to 2021
$37.6M
MN Regional Cardiovascular Cell Therapy Clinical Res. Network: From AMI to PADUM1HL087394 · NHLBI · UNIVERSITY OF MINNESOTA · PI HENRY, TIMOTHY D · 2012 to 2018
$5.1M
Cell Characterization and Imaging for Regenerative Therapies in Ischemic DiseasesUM1HL113456 · NHLBI · STANFORD UNIVERSITY · PI YANG, PHILLIP CHUNG-MING · 2012 to 2018
$3.3M
University of Louisville Regional Clinical Center for the CCTRNUM1HL113530 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2012 to 2018
$2.9M
Patient Oriented Research in Cardiovascular RegenerationK24HL130553 · NHLBI · STANFORD UNIVERSITY · PI YANG, PHILLIP CHUNG-MING · 2016 to 2020
$584k
Using Exosomes to Preserve Viability and Function in Anthracycline Induced Cardiomyopathy Patient Specific Cardiomyocytes After Exposure to DoxorubicinF32HL139046 · NHLBI · STANFORD UNIVERSITY · PI O'BRIEN, CONNOR · 2017 to 2018
$126k
NHLBI NIH HHS F32 HL139046NHLBI NIH HHS K24 HL130553NHLBI NIH HHS P01 HL078825NHLBI NIH HHS UM1 HL087394NHLBI NIH HHS UM1 HL113456NHLBI NIH HHS UM1 HL113530
6 · The paper itself

Abstract

backgroundMononuclear cells (MNCs) have been tested in clinical trials across multiple cardiovascular pathologies with mixed results. Major adverse cardiac events (MACE) and markers of cardiovascular capacity have been particularly challenging to interpret because of small size. This meta-analysis is aimed to assess the efficacy of MNC therapy in randomized clinical trials to identify the markers of efficiency that could influence future trial design.

methodsPubMed, Embase, Cochrane library, and ClinicalTrials.gov were searched from inception through November 8, 2018. Changes in left ventricular ejection fraction (LVEF) and infarct size from baseline to follow-up were selected as primary outcomes. Changes in the left ventricular end-systolic volume, left ventricular end-diastolic volume, brain natriuretic peptide/N-terminal pro-B-type natriuretic peptide, 6-minute walk test, New York Heart Association class, and MACE incidences were considered secondary outcomes.

resultsIn short-term follow-up, patients treated with MNCs demonstrated a significant increase in absolute LVEF of 2.21% (95% CI 1.59-2.83; P < .001; I

conclusionsMNC therapy may convey a modest but sustained increase in LVEF in ischemic cardiomyopathy patients, supporting further investigation. AMI trials, however, demonstrated minimal improvement in LVEF of unclear clinical significance, suggesting a limited role for MNC therapy in AMI.

Indexed as

Randomized Controlled Trials as TopicAgedFemaleFollow-Up StudiesHumansLeukocytes, MononuclearMaleMiddle AgedMyocardial InfarctionNatriuretic Peptide, BrainOutcome Assessment, Health CarePeptide FragmentsSeverity of Illness IndexStroke VolumeTime FactorsTreatment OutcomeNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID31821904
PMCPMC7173405
OpenAlexW2989330633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.